8th Baltic Congress of Radiology

08.10.2022 Tallinn, Estonia

PSMA PET/CT in prostate cancer diagnostics

Tiina Kärner (Estonia)

Radiologist / nuclear medicine physician, Tartu University Hospital

Biography: I graduated from the University of Tartu in 2009, then completed a 4-year specialization in radiology, and since 2013 I have been working in the nuclear medicine department of Tartu University Hospital. On a daily basis, I deal with both PET/CT and conventional nuclear medical examinations, as well as radioisotope treatment of patients.

Presentation

Small Hall

Synopsis: PSMA (Prostate Specific Membrane Antigen) PET/CT is a novel diagnostic method for detecting prostate cancer lesions. It has proved to be more accurate than previosly widely used conventional radiological methods and in most European countries has become the gold standard for staging of primary high progression-risk cancer and for detecting cancer lesions in biochemical recurrence patients. It is also used to assess patient eligibility for 177Lu-PSMA treatment and can be used to evaluate treatment effect or disease dynamics. To date, Tartu University Hospital has 4.5 years of experience in performing 18F PSMA PET/CT examinations.

This agenda item is presented in the following session: S5-2 Prostata Imaging

Plenary session

08.10.2022 09:00 - 10:30